Related Experiment Videos

Drug development and the importance of ethnicity: lessons from heart failure management and implications for

Michael D Sosin1, Gurbir S Bhatia, Gregory Y H Lip

  • 1University Department of Medicine, Sandwell & West Birmingham Hospitals NHS Trust, City Hospital, Birmingham B18 7QH, England, UK.

Current Pharmaceutical Design
|December 8, 2004
PubMed

Insights

Heart failure is rising globally, with ethnic disparities in prevalence and treatment effectiveness. Research is needed to ensure therapies like ACE inhibitors benefit all ethnic groups, including South Asian and African Caribbean populations.

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacology

Background:

  • Heart failure (HF) prevalence is increasing globally, particularly in aging Western populations.
  • Significant HF patient proportions in the UK belong to South Asian and African Caribbean ethnic groups.
  • Potential ethnic variations in HF epidemiology, pathophysiology, and treatment response exist.

Purpose of the Study:

  • To review current evidence on heart failure management considering patient ethnicity.
  • To explore implications for future drug development in cardiovascular medicine.
  • To examine considerations for antihypertensive therapy across diverse ethnic groups.

Main Methods:

  • Literature review of existing studies on heart failure and ethnicity.
  • Analysis of epidemiological and pathophysiological data across ethnic groups.
  • Evaluation of clinical trial data for treatments like ACE inhibitors in diverse populations.

Main Results:

  • Evidence suggests potential differences in heart failure presentation and progression among ethnic groups.
  • Current heart failure treatment guidelines and evidence bases are predominantly based on white populations.
  • The efficacy of standard therapies, such as ACE inhibitors, may vary across ethnic groups.

Conclusions:

  • Ethnic background is a critical factor in heart failure management.
  • Future research and drug development must address ethnic variations for equitable and effective cardiovascular care.
  • Personalized antihypertensive strategies considering ethnicity are crucial for improving heart failure outcomes.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...